Trial Profile
A 12-month, Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of 0.5 mg Ranibizumab Dosed PRN in Subjects With Visual Impairment Due to Diabetic Macular Edema in Chinese Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Apr 2019
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema; Vision disorders
- Focus Registrational; Therapeutic Use
- Acronyms REFINE
- Sponsors Novartis Pharmaceuticals
- 01 Mar 2019 Primary endpoint (Mean Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) (Letters) to Month 1 Through 12) has been met as per results published in the Graefes Archive for Clinical and Experimental Ophthalmology
- 01 Mar 2019 Results published in the Graefes Archive for Clinical and Experimental Ophthalmology
- 29 Mar 2017 Status changed from active, no longer recruiting to completed.